ATE307609T1 - Präventiva/mittel zur glaukombehandlung - Google Patents

Präventiva/mittel zur glaukombehandlung

Info

Publication number
ATE307609T1
ATE307609T1 AT99937073T AT99937073T ATE307609T1 AT E307609 T1 ATE307609 T1 AT E307609T1 AT 99937073 T AT99937073 T AT 99937073T AT 99937073 T AT99937073 T AT 99937073T AT E307609 T1 ATE307609 T1 AT E307609T1
Authority
AT
Austria
Prior art keywords
glaucoma
treatment
prophylaxis
agent
compound
Prior art date
Application number
AT99937073T
Other languages
English (en)
Inventor
Mitsuyoshi Azuma
Yukuo Yoshida
Mitsunori Waki
Masayoshi Uehata
Original Assignee
Senju Pharma Co
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co, Mitsubishi Pharma Corp filed Critical Senju Pharma Co
Application granted granted Critical
Publication of ATE307609T1 publication Critical patent/ATE307609T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99937073T 1998-08-17 1999-08-13 Präventiva/mittel zur glaukombehandlung ATE307609T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP24776298 1998-08-17
JP12296099 1999-04-28
PCT/JP1999/004403 WO2000009162A1 (en) 1998-08-17 1999-08-13 Preventives/remedies for glaucoma

Publications (1)

Publication Number Publication Date
ATE307609T1 true ATE307609T1 (de) 2005-11-15

Family

ID=26459997

Family Applications (3)

Application Number Title Priority Date Filing Date
AT04014077T ATE527993T1 (de) 1998-08-17 1999-08-13 Verbindung zur vorbeugung und behandlung von augen-asthenopie und pseudomyopie
AT04014078T ATE529102T1 (de) 1998-08-17 1999-08-13 Verbindung zur vorbeugung und behandlung von glaukoma
AT99937073T ATE307609T1 (de) 1998-08-17 1999-08-13 Präventiva/mittel zur glaukombehandlung

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT04014077T ATE527993T1 (de) 1998-08-17 1999-08-13 Verbindung zur vorbeugung und behandlung von augen-asthenopie und pseudomyopie
AT04014078T ATE529102T1 (de) 1998-08-17 1999-08-13 Verbindung zur vorbeugung und behandlung von glaukoma

Country Status (11)

Country Link
US (2) US6673812B1 (de)
EP (3) EP1459743B9 (de)
JP (2) JP3720264B2 (de)
KR (1) KR100616466B1 (de)
CN (2) CN1195547C (de)
AT (3) ATE527993T1 (de)
AU (1) AU5198199A (de)
CA (2) CA2307285C (de)
DE (1) DE69927936T2 (de)
ES (3) ES2374518T3 (de)
WO (1) WO2000009162A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100444843C (zh) * 1998-08-10 2008-12-24 旭化成制药株式会社 法舒地尔盐酸盐缓释口服制剂
WO2000057914A1 (en) * 1999-03-25 2000-10-05 Santen Pharmaceutical Co., Ltd. Ocular tension-lowering agents
WO2000057913A1 (en) * 1999-03-25 2000-10-05 Welfide Corporation Preventives/remedies for interstitial pneumonia and pulmonary fibrosis
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
JP2004509876A (ja) 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４−アミノ−キナゾリン
US7109208B2 (en) 2001-04-11 2006-09-19 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents
JP2003010158A (ja) * 2001-04-26 2003-01-14 Biochemical & Pharmacological Laboratories Inc 眼精疲労モデル、その作製方法、そのモデルを用いた評価方法およびその評価法を用いて選択された薬剤
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
EP1470121B1 (de) 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidin-derivate als rho kinase inhibitoren
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
AU2003257588A1 (en) 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
AU2003280812A1 (en) * 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
CN100390173C (zh) * 2003-06-06 2008-05-28 旭化成制药株式会社 3环系化合物
EP1679308B1 (de) 2003-10-15 2013-07-24 Ube Industries, Ltd. Neues indazolderivat
JP2007512347A (ja) * 2003-11-26 2007-05-17 デューク・ユニバーシティー 緑内障を予防するかまたは治療する方法
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
US7083783B2 (en) * 2004-02-18 2006-08-01 Wisconsin Alumni Research Foundation Method for treating glaucoma
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
FR2868310A1 (fr) * 2004-04-02 2005-10-07 Oreal Utilisation cosmetique d'au moins un inhibiteur de la production et/ou de l'activation des rhoa kinases comme agent destine a detendre les traits et/ou decontracter la peau
US7485654B2 (en) * 2004-06-03 2009-02-03 Senju Pharmaceutical Co., Ltd. Corneal perception recovery drug containing amide compound
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
MX2007007797A (es) * 2004-12-27 2007-08-23 Alcon Inc Analogo de aminopirazina para tratar glaucoma y otras enfermedades mediadas por rho cinasa.
RU2288675C2 (ru) * 2005-01-19 2006-12-10 Рудольф Алексеевич Герасимов Способ лечения псевдомиопии
WO2006088088A1 (ja) * 2005-02-16 2006-08-24 Astellas Pharma Inc. Ｒｏｃｋ阻害剤を含有する疼痛治療剤
CN101198354B (zh) * 2005-06-21 2012-01-11 兴和株式会社 青光眼的预防或治疗剂
KR101333990B1 (ko) 2005-07-12 2013-11-27 코와 가부시키가이샤 녹내장을 예방 또는 치료하는 약제
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
MX2008008328A (es) 2005-12-22 2008-09-15 Alcon Res Ltd (indazol-5-il)-pirazinas y (1,3-dihidro-indol-2-ona)-pirazinas para tratar enfermedades y condiciones mediadas con rho cinasa.
RU2008152065A (ru) 2006-06-08 2010-07-20 Убе Индастриз, Лтд (Jp) Новое производное имидазола со спироциклической структурой в боковой цепи
BRPI0714782A2 (pt) * 2006-07-31 2013-07-16 Senju Pharma Co preparaÇço lÍquida aquosa contendo composto de amida
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
WO2008078762A1 (ja) 2006-12-26 2008-07-03 Santen Pharmaceutical Co., Ltd. ウレア構造を有する新規ｎ－(２－アミノフェニル)ベンズアミド誘導体
EP2133339A4 (de) 2007-03-28 2010-04-21 Santen Pharmaceutical Co Ltd Neues (2-aminophenyl)pyridincarboxamidderivat mit harnstoffstruktur
JP2008266322A (ja) 2007-03-28 2008-11-06 Santen Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8968396B2 (en) 2007-07-23 2015-03-03 Powervision, Inc. Intraocular lens delivery systems and methods of use
WO2009028631A1 (ja) * 2007-08-29 2009-03-05 Senju Pharmaceutical Co., Ltd. 角膜内皮細胞接着促進剤
WO2009038243A1 (en) * 2007-09-21 2009-03-26 Eyegene, Inc. Composition for treating retinopathy or glaucoma comprising thrombin derived peptides
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
AU2009221859B2 (en) 2008-03-05 2013-04-18 Alcon Inc. Methods and apparatus for treating glaucoma
ES2389754T3 (es) * 2008-05-23 2012-10-31 Santen Pharmaceutical Co., Ltd Nuevos derivados de tiofendiamina con estructura urea
KR20110042054A (ko) * 2008-07-24 2011-04-22 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 축성 근시의 예방 또는 치료제
WO2010010715A1 (ja) 2008-07-25 2010-01-28 旭化成ファーマ株式会社 スルホンアミド化合物を含有する安定な水溶液組成物
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US20110166161A1 (en) * 2008-09-18 2011-07-07 Astellas Pharma Inc. Heterocyclic carboxamide compounds
US10272035B2 (en) * 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US9693899B2 (en) 2009-07-09 2017-07-04 Ivantis, Inc. Single operator device for delivering an ocular implant
JP5635605B2 (ja) 2009-07-09 2014-12-03 イバンティス インコーポレイテッド 眼内インプラント及び眼内インプラントを眼球内に送出するための方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
EP3263574B1 (de) 2010-02-23 2019-04-03 PowerVision, Inc. Akkomodative intraokularlinse
EP2597953A4 (de) * 2010-07-27 2013-12-25 Inspire Pharmaceuticals Inc Verfahren zur behandlung von augenkrankheiten unter verwendung von kinasehemmerverbindungen in prodrug-formen
ES2684351T3 (es) 2011-02-04 2018-10-02 Kowa Co., Ltd. Terapia farmacológica para prevenir o tratar glaucoma
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CA3099517C (en) * 2012-07-13 2022-04-26 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
WO2014085450A1 (en) 2012-11-28 2014-06-05 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
EP2967842B1 (de) 2013-03-15 2020-11-04 Alcon Inc. Verfahren zum rekonfigurieren einer intraokularlinse zur abgabe an eine abgabevorrichtung
JP5557408B1 (ja) 2013-04-24 2014-07-23 国立大学法人九州大学 眼底疾患治療剤
WO2016011056A1 (en) 2014-07-14 2016-01-21 Ivantis, Inc. Ocular implant delivery system and method
US9844556B2 (en) 2015-03-25 2017-12-19 Megumi Honjo Preventive/therapeutic method and preventive/therapeutic agent for complications after cataract surgery
EP4265231A3 (de) 2015-08-14 2023-12-20 Alcon Inc. Augenimplantat mit drucksensor
US12048761B2 (en) 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (de) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von kapillarer nichtperfusion der netzhaut
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
WO2019124488A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬
EP3755287B1 (de) 2018-02-22 2024-04-03 Alcon Inc. Augenimplantat
US12473284B2 (en) * 2019-12-30 2025-11-18 Memorial Sloan Kettering Cancer Center Small molecule inhibitors of ULK1
EP4100014B1 (de) 2020-02-05 2024-01-03 Nicox S.A. Zusammensetzungen zur behandlung von glaukom und augenhochdruck
CA3202776A1 (en) 2021-01-11 2022-07-14 Wayne A. Noda Systems and methods for viscoelastic delivery
TW202237083A (zh) 2021-01-11 2022-10-01 美商英塞特公司 包含ｊａｋ路徑抑制劑及ｒｏｃｋ抑制劑之組合療法
EP4734876A1 (de) 2023-06-30 2026-05-06 Alcon Inc. System und verfahren zur kompensation der neigung einer intraokularlinse
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838677A (en) 1987-04-06 1989-06-13 Ayetech Inc. Eye exercising devices
US5250547A (en) * 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
KR0133372B1 (ko) 1991-09-06 1998-04-23 고야 다다시 4-아미노(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
IL104755A0 (en) * 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
US5618955A (en) 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
IL103932A (en) * 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
JP3066561B2 (ja) * 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
JPH07133225A (ja) * 1993-11-09 1995-05-23 Santen Pharmaceut Co Ltd 毛様体筋緊張緩和剤
EP1195372A1 (de) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung
JPH08198876A (ja) * 1995-01-30 1996-08-06 Yoshitomi Pharmaceut Ind Ltd トランス−Ｎ−（１Ｈ−ピラゾロ〔３，４−ｂ〕ピリジン−４−イル）−４−グアニジノメチルシクロヘキサンカルボキサミド・１メタンスルホン酸塩・１水和物
US5888173A (en) 1995-08-10 1999-03-30 Singhal; Tara Chand Health saver computer break
JP3421217B2 (ja) * 1995-11-20 2003-06-30 麒麟麦酒株式会社 Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
US5906819A (en) 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
JPH09143099A (ja) * 1995-11-27 1997-06-03 Santen Pharmaceut Co Ltd 毛様体筋緊張緩和剤
ATE289815T1 (de) 1995-12-21 2005-03-15 Alcon Lab Inc Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
BR9711154A (pt) 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho

Also Published As

Publication number Publication date
ATE529102T1 (de) 2011-11-15
CA2635412C (en) 2011-06-21
US6673812B1 (en) 2004-01-06
JP2004277432A (ja) 2004-10-07
CA2307285C (en) 2009-03-31
KR100616466B1 (ko) 2006-08-29
EP1034793B1 (de) 2005-10-26
EP1459743A3 (de) 2007-12-26
CN1494903A (zh) 2004-05-12
EP1459742A3 (de) 2007-12-26
WO2000009162A1 (en) 2000-02-24
JP4490748B2 (ja) 2010-06-30
EP1459743B1 (de) 2011-10-19
HK1069121A1 (en) 2005-05-13
CA2635412A1 (en) 2000-02-24
ES2372572T3 (es) 2012-01-23
US6649625B2 (en) 2003-11-18
CN1195547C (zh) 2005-04-06
EP1034793A4 (de) 2003-07-09
EP1459742A2 (de) 2004-09-22
DE69927936T2 (de) 2006-06-29
EP1459742B1 (de) 2011-10-12
EP1459743A8 (de) 2005-02-02
US20030125351A1 (en) 2003-07-03
EP1459742B9 (de) 2012-05-02
DE69927936D1 (de) 2005-12-01
CA2307285A1 (en) 2000-02-24
ES2247822T3 (es) 2006-03-01
HK1069120A1 (en) 2005-05-13
HK1030883A1 (en) 2001-05-25
EP1459743A2 (de) 2004-09-22
KR20010015761A (ko) 2001-02-26
AU5198199A (en) 2000-03-06
EP1459743B9 (de) 2012-08-01
ATE527993T1 (de) 2011-10-15
EP1034793A1 (de) 2000-09-13
CN1287494A (zh) 2001-03-14
ES2374518T3 (es) 2012-02-17
JP3720264B2 (ja) 2005-11-24
CN1293878C (zh) 2007-01-10

Similar Documents

Publication Publication Date Title
ATE307609T1 (de) Präventiva/mittel zur glaukombehandlung
PT868186E (pt) Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
DE69317044D1 (de) Mittel zur regulierung vom hautfettigkeitsgrad
CY1108651T1 (el) Προληπτικος ή θεραπευτικος παραγων για γλαυκωμα
ATE374026T1 (de) Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose
WO2002098350A3 (en) Pyranoindazoles and their use for the treatment of glaucoma
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
TR200003280T2 (tr) Katarakt çıkarma için cerrahi prosedürlerin kolaylaştırılması için bir vital boyanın kullanımı.
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
WO2003005941A3 (de) Insert zur behandlung des trockenen auges
DE3872701D1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
DK1075284T3 (da) Anvendelse af et vitalt farvestof til at lette kirugiske indgreb i forbindelse med vitreoretinal kurugi
TW200501949A (en) Ophthalmic compositions for treating ocular hypertension
EP2062872A3 (de) Verwendung von Bisaminen zur Verstärkung der antimikrobiellen Wirkung von wässrigen Zusammensetzungen
BR0017158A (pt) Agonistas de 5ht2 para controlar a iop e tratar o glaucoma
MXPA03005922A (es) Metodo para tratar glaucoma ib.
ATE409491T1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
HU9902097D0 (en) Method for treating glaucoma
BR0316775A (pt) Novos análogos de benzopirano e seu uso para o tratamento de glaucoma
BR0017168A (pt) Piranoindóis para tratamento de glaucoma
WO2002060339A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2002023784A3 (en) Cysteine protease inhibitors
WO2001035948A3 (en) Neurophilin ligands for treating ocular conditions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties